Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AG13909 in Adults with Cushing’s Disease
2023-504733-53-00Phase 2Authorised
- Sponsor
- Lundbeck
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, open-label trial of Lu AG13909 in Corticotropin adenoma (ACTHoma) (2 arms), sponsored by Lundbeck. Primary endpoints: UFC complete response at end of IV/SC titration (Part A & B), Treatment-emergent adverse events and 9 more. Planned start Sep 2024; status: authorised.
02
Drugs
Lu AG13909
03
Conditions
Corticotropin adenoma (ACTHoma)
Beyond the preview
Go deeper on 2023-504733-53-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504733-53-00.